 Chemokine CCL5
"Chemokine CCL5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CC-type chemokine that is a chemoattractant for EOSINOPHILS; MONOCYTES; and LYMPHOCYTES. It is a potent and selective eosinophil chemotaxin that is stored in and released from PLATELETS and activated T-LYMPHOCYTES. Chemokine CCL5 is specific for CCR1 RECEPTORS; CCR3 RECEPTORS; and CCR5 RECEPTORS. The acronym RANTES refers to Regulated on Activation, Normal T Expressed and Secreted.
| Descriptor ID |
D018946
|
| MeSH Number(s) |
D12.644.276.374.200.110.250 D12.776.467.374.200.110.250 D23.125.300.110.250 D23.469.200.110.250 D23.529.374.200.110.250
|
| Concept/Terms |
Chemokine CCL5- Chemokine CCL5
- CCL5, Chemokine
- RANTES Protein, T-Cell
- RANTES Protein, T Cell
- T-Cell RANTES Protein
- CCL5 Chemokine
- Chemokine, CCL5
- RANTES
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CCL5".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CCL5".
This graph shows the total number of publications written about "Chemokine CCL5" by people in this website by year, and whether "Chemokine CCL5" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 3 | 3 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2017 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2022 | 1 | 0 | 1 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemokine CCL5" by people in Profiles.
-
Gauthier M, Kale SL, Oriss TB, Gorry M, Ramonell RP, Dalton K, Ray P, Fahy JV, Seibold MA, Castro M, Jarjour N, Gaston B, Bleecker ER, Meyers DA, Moore W, Hastie AT, Israel E, Levy BD, Mauger D, Erzurum S, Comhair SA, Wenzel SE, Ray A. CCL5 is a potential bridge between type 1 and type 2 inflammation in asthma. J Allergy Clin Immunol. 2023 07; 152(1):94-106.e12.
-
Fonteh CN, Palestine AG, Wagner BD, Patnaik JL, Mathias MT, Manoharan N, Mandava N, Baldermann R, De Carlo T, Lynch AM. RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration. Transl Vis Sci Technol. 2023 01 03; 12(1):19.
-
Fonteh CN, Palestine AG, Wagner BD, Patnaik JL, Mathias MT, Mandava N, Baldermann R, Lynch AM. Sex Differences in RANTES (CCL5) in Patients With Intermediate Age-Related Macular Degeneration (AMD) and Controls With no AMD. Transl Vis Sci Technol. 2022 Feb 01; 11(2):12.
-
Delaney C, Davizon-Castillo P, Allawzi A, Posey J, Gandjeva A, Neeves K, Tuder RM, Di Paola J, Stenmark KR, Nozik ES. Platelet activation contributes to hypoxia-induced inflammation. Am J Physiol Lung Cell Mol Physiol. 2021 03 01; 320(3):L413-L421.
-
Mitra S, Schiller D, Anderson C, Gamboni F, D'Alessandro A, Kelher M, Silliman CC, Banerjee A, Jones KL. Hypertonic saline attenuates the cytokine-induced pro-inflammatory signature in primary human lung epithelia. PLoS One. 2017; 12(12):e0189536.
-
Guan X, Chaffey PK, Chen H, Feng W, Wei X, Yang LM, Ruan Y, Wang X, Li Y, Barosh KB, Tran AH, Zhu J, Liang W, Zheng YT, Wang X, Tan Z. O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor. Biochemistry. 2018 01 09; 57(1):136-148.
-
Stolberg VR, McCubbrey AL, Freeman CM, Brown JP, Crudgington SW, Taitano SH, Saxton BL, Mancuso P, Curtis JL. Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function. J Immunol. 2015 Jul 01; 195(1):174-84.
-
Sottnik JL, Dai J, Zhang H, Campbell B, Keller ET. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 2015 Jun 01; 75(11):2151-8.
-
Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65.
-
McCarthy MK, Levine RE, Procario MC, McDonnell PJ, Zhu L, Mancuso P, Crofford LJ, Aronoff DM, Weinberg JB. Prostaglandin E2 induction during mouse adenovirus type 1 respiratory infection regulates inflammatory mediator generation but does not affect viral pathogenesis. PLoS One. 2013; 8(10):e77628.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|